- All-in-One CT Analysis Enhances Efficiency in Public Healthcare
Coreline Soft announced on November 10 that its artificial intelligence (AI) software, AVIEW, has exceeded 2.5 million medical readings across more than 200 hospitals in 19 countries.
The company’s flagship AI platform has recently been adopted as an official medical AI solution in several government-led lung cancer screening projects across major European nations. Coreline Soft emphasized that this trend signifies a global shift in recognizing AI not merely as an assistive tool, but as a core component of national healthcare infrastructure. With Germany and other countries issuing official AI adoption guidelines, the firm expects its presence to expand significantly across Europe.
In the European market, Coreline Soft is strengthening its participation in national-scale lung cancer screening programs in Germany, Italy, and France, while accelerating regional expansion based on EU CE certification.
In the United States, the company has successfully entered the insurance reimbursement market through its localization strategy. It has established collaborations with Baylor College of Medicine (Texas Medical Center), 3DR Labs, and UMass Memorial Medical Center, while conducting clinical research with the Temple Lung Center and co-developing malignancy prediction technology with Oatmeal Health. These efforts underscore Coreline Soft’s growing footprint in the U.S. healthcare ecosystem.
Domestically, Coreline Soft has operated Korea’s National Lung Cancer Screening Quality Management and Information System for nine consecutive years since 2017, positioning itself as a key partner in the public healthcare infrastructure. The company was also selected for multiple national AI research and development projects, including a KRW 22 billion multimodal AI initiative, further strengthening its technological leadership.
A Coreline Soft spokesperson noted, “Through strategic execution from technical validation to commercialization and revenue diversification, we have secured recognition from multiple governments as a trusted medical AI provider. We will continue sustainable global expansion by combining stable public-sector projects with the high-growth U.S. market.”
The company’s main product, AVIEW LCS Plus, is an All-in-One AI platform capable of analyzing lung nodules, emphysema, and coronary artery calcification simultaneously from a single low-dose CT scan. This enables early detection not only of lung cancer but also of chronic obstructive pulmonary disease (COPD) and cardiovascular conditions, significantly enhancing the efficiency of public health management.
Coreline Soft will showcase its solutions at RSNA 2025, held from November 30 to December 4 in Chicago, where it will present its global strategy and conduct a live demonstration of end-to-end AI workflows in the “Radiology Reimagined” demo zone.
